50.90
Sanofi Adr stock is traded at $50.90, with a volume of 3.73M.
It is up +1.52% in the last 24 hours and up +2.02% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$50.14
Open:
$50.37
24h Volume:
3.73M
Relative Volume:
1.27
Market Cap:
$124.96B
Revenue:
$43.23B
Net Income/Loss:
$6.79B
P/E Ratio:
12.71
EPS:
4.0051
Net Cash Flow:
$9.17B
1W Performance:
+11.77%
1M Performance:
+2.02%
6M Performance:
-6.81%
1Y Performance:
-8.35%
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
50.90 | 122.19B | 43.23B | 6.79B | 9.17B | 4.0051 |
![]()
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
![]()
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
![]()
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
![]()
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
Mar-21-25 | Initiated | Goldman | Neutral |
Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
Jul-26-24 | Reiterated | Argus | Buy |
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-30-23 | Downgrade | Stifel | Buy → Hold |
Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-13-22 | Resumed | Morgan Stanley | Overweight |
Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
Aug-09-22 | Downgrade | UBS | Buy → Neutral |
May-23-22 | Initiated | SVB Leerink | Outperform |
Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jan-15-21 | Initiated | Deutsche Bank | Sell |
Sep-29-20 | Initiated | Berenberg | Hold |
Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-03-19 | Initiated | Bernstein | Outperform |
Aug-14-19 | Upgrade | UBS | Neutral → Buy |
Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
Mar-23-18 | Upgrade | Liberum | Hold → Buy |
Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Benzinga
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva
What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm
Why Is Sanofi Stock Falling Thursday? - Sahm
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm
New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha
Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):